Memantine and Raloxifene for Cognitive Preservation After Brain Radiation
This study is looking at whether combining two medications, memantine and raloxifene, can help prevent memory problems in people receiving radiation therapy for brain cancer. Radiation to the brain can sometimes cause cognitive (thinking and memory) issues. Researchers want to see if adding raloxifene to memantine, which is already used to protect brain cells, can further reduce these side effects. The study will measure changes in the size of the hippocampus (a part of the brain important for memory) over 48 weeks. Anyone aged 18 or older who is having radiation for brain cancer and meets other health criteria may be able to join. The study is currently recruiting 108 participants.
- Study design
- This interventional study plans to enroll 108 participants. It is testing memantine, alone or with raloxifene, to see if it can protect brain function after radiation.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for changes in hippocampal volume from the start of the study up to 48 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
At a glance
Conditions
NCT07470606
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mays Cancer Center, UT Health San Antonio
San Antonio, Texasstudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Hippocampal volume changesBaseline to 48 weeks
MRIs will be used to capture any changes in hippocampal volume